Literature DB >> 22245663

NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia.

John A Saunders1, Michael J Gandal, Steve J Siegel.   

Abstract

RATIONALE: There is increasing evidence that functional deficits in schizophrenia may be driven by a reduction in the signal-to-noise ratio (SNR) and consistent timing of neural signals. This study examined the extent to which exposure to the NMDA receptor antagonists ketamine and MK801, frequently used pharmacological models of schizophrenia, recreate deficits in electrophysiological markers of disturbed brain circuits that are thought to underlie the illness. Furthermore, this study characterizes the specificity of these differences across the frequency spectrum so as to help identify the nature of selective circuit abnormalities that mediate each oscillatory response as relevant to schizophrenia.
DESIGN: Mouse EEG was recorded during exposure to repeated auditory stimuli after injection of either vehicle or drug. The dose-response relationship for each electrophysiological measure was determined for ketamine and MK-801. Time-frequency analyses were performed to assess baseline, total, and evoked power and intertrial coherence (ITC) at low (5-10 Hz) and high (35-80 Hz)-frequencies.
RESULTS: High frequency evoked and total power was decreased by MK-801 and ketamine in a dose-dependent fashion. High frequency baseline power was increased by MK-801 and ketamine in a dose-dependent fashion. Similar to evoked power, high frequency inter-trial coherence was dose-dependently decreased by both drugs. Low frequency ITC was only decreased by ketamine.
CONCLUSIONS: Both ketamine and MK-801 cause alterations in high-frequency baseline (noise), total (signal), and evoked (signal) power resulting in a loss of high frequency SNR that is thought to primarily reflect local circuit activity. These changes indicate an inappropriate increase in baseline activity, which can also be interpreted as non-task related activity. Ketamine induced a loss of intertrial coherence at low frequencies, indicating a loss of consistency in low-frequency circuit mechanisms. As a proportion of baseline power, both drugs had a relative shift from low to high frequencies, reflecting a change in the balance of brain activity from coordination of global regions to a pattern of discoordinated, autonomous local activity. These changes are consistent with a pattern of fragmented regional brain activity seen in schizophrenia. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245663      PMCID: PMC4161042          DOI: 10.1016/j.nbd.2011.12.049

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  77 in total

1.  Frequency of gamma oscillations routes flow of information in the hippocampus.

Authors:  Laura Lee Colgin; Tobias Denninger; Marianne Fyhn; Torkel Hafting; Tora Bonnevie; Ole Jensen; May-Britt Moser; Edvard I Moser
Journal:  Nature       Date:  2009-11-19       Impact factor: 49.962

2.  Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia.

Authors:  T B Halene; R S Ehrlichman; Y Liang; E P Christian; G J Jonak; T L Gur; J A Blendy; H C Dow; E S Brodkin; F Schneider; R C Gur; S J Siegel
Journal:  Genes Brain Behav       Date:  2009-05-08       Impact factor: 3.449

3.  Event-related potential abnormalities in schizophrenia: a failure to "gate in" salient information?

Authors:  Colleen A Brenner; Paul D Kieffaber; Brett A Clementz; Jason K Johannesen; Anantha Shekhar; Brian F O'Donnell; William P Hetrick
Journal:  Schizophr Res       Date:  2009-07-23       Impact factor: 4.939

4.  Parvalbumin neurons and gamma rhythms enhance cortical circuit performance.

Authors:  Vikaas S Sohal; Feng Zhang; Ofer Yizhar; Karl Deisseroth
Journal:  Nature       Date:  2009-04-26       Impact factor: 49.962

5.  Steady state and induced auditory gamma deficits in schizophrenia.

Authors:  G P Krishnan; W P Hetrick; C A Brenner; A Shekhar; A N Steffen; B F O'Donnell
Journal:  Neuroimage       Date:  2009-04-14       Impact factor: 6.556

6.  Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions.

Authors:  Richard S Ehrlichman; Steven N Luminais; Samantha L White; Noam D Rudnick; Nan Ma; Holly C Dow; Arati S Kreibich; Ted Abel; Edward S Brodkin; Chang-Gyu Hahn; Steven J Siegel
Journal:  Brain Res       Date:  2009-07-28       Impact factor: 3.252

Review 7.  Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.

Authors:  Pablo A Gaspar; M Leonor Bustamante; Hernán Silva; Francisco Aboitiz
Journal:  J Neurochem       Date:  2009-08-04       Impact factor: 5.372

8.  Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials.

Authors:  Laura C Amann; Tobias B Halene; Richard S Ehrlichman; Stephen N Luminais; Nan Ma; Ted Abel; Steven J Siegel
Journal:  Neurobiol Dis       Date:  2009-05-23       Impact factor: 5.996

9.  NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness.

Authors:  Tahir Hakami; Nigel C Jones; Elena A Tolmacheva; Julien Gaudias; Joseph Chaumont; Michael Salzberg; Terence J O'Brien; Didier Pinault
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

Review 10.  Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?

Authors:  M Margarita Behrens; Terrence J Sejnowski
Journal:  Neuropharmacology       Date:  2009-06-11       Impact factor: 5.250

View more
  31 in total

1.  NMDA antagonist MK801 recreates auditory electrophysiology disruption present in autism and other neurodevelopmental disorders.

Authors:  John A Saunders; Michael J Gandal; Timothy P Roberts; Steve J Siegel
Journal:  Behav Brain Res       Date:  2012-07-05       Impact factor: 3.332

Review 2.  Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.

Authors:  James M McNally; Robert W McCarley
Journal:  Curr Opin Psychiatry       Date:  2016-05       Impact factor: 4.741

3.  Gamma rhythms link prefrontal interneuron dysfunction with cognitive inflexibility in Dlx5/6(+/-) mice.

Authors:  Kathleen K A Cho; Renee Hoch; Anthony T Lee; Tosha Patel; John L R Rubenstein; Vikaas S Sohal
Journal:  Neuron       Date:  2015-03-05       Impact factor: 17.173

4.  Alterations in High-Frequency Neuronal Oscillations in a Cynomolgus Macaque Test of Sustained Attention Following NMDA Receptor Antagonism.

Authors:  Anushka V Goonawardena; Jaime Heiss; Courtney Glavis-Bloom; Gerhard Trube; Edilio Borroni; Daniela Alberati; Tanya L Wallace
Journal:  Neuropsychopharmacology       Date:  2015-09-10       Impact factor: 7.853

Review 5.  Ketamine and phencyclidine: the good, the bad and the unexpected.

Authors:  D Lodge; M S Mercier
Journal:  Br J Pharmacol       Date:  2015-07-28       Impact factor: 8.739

Review 6.  Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis.

Authors:  Andrew M Rosen; Timothy Spellman; Joshua A Gordon
Journal:  Biol Psychiatry       Date:  2015-03-27       Impact factor: 13.382

Review 7.  Cellular and circuit models of increased resting-state network gamma activity in schizophrenia.

Authors:  R S White; S J Siegel
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

8.  The electrophysiological signature of motivational salience in mice and implications for schizophrenia.

Authors:  Carolin Moessnang; Ute Habel; Frank Schneider; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2012-08-22       Impact factor: 7.853

9.  Animal Models of Psychosis: Current State and Future Directions.

Authors:  Alexandra D Forrest; Carlos A Coto; Steven J Siegel
Journal:  Curr Behav Neurosci Rep       Date:  2014-06-01

10.  Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks.

Authors:  Neil Dawson; Martin McDonald; Desmond J Higham; Brian J Morris; Judith A Pratt
Journal:  Neuropsychopharmacology       Date:  2014-02-04       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.